To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test
Read time: Less than a minute
TcLand Expression SA has announced the launch of the KARE study (Kidney Allograft REjection).
This will be the international, multicentre, prospective clinical validation study for TcLand Expression’s K-RejX qPCR blood test, as a multi-gene molecular diagnostic tool to help in the identification of kidney transplant recipients at risk of chronic antibody-mediated rejection (CAMR). The KARE study will enroll 450 patients from over 30 European and North American large transplantation centers.
This will be the international, multicentre, prospective clinical validation study for TcLand Expression’s K-RejX qPCR blood test, as a multi-gene molecular diagnostic tool to help in the identification of kidney transplant recipients at risk of chronic antibody-mediated rejection (CAMR). The KARE study will enroll 450 patients from over 30 European and North American large transplantation centers.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
